Jianan Huang outlines the market prospects for first-line treatments for liver cancer treatment in China.
Jianan Huang discusses how the drug revenue formula is being used to guide R&D "rescue strategies".
Joanna Huang analyses the use of external innovation tools among small and large pharma in China.